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Abstract
The canine lymphoma blood test detects the levels of two biomarkers, the acute phase
proteins (C-Reactive Protein and Haptoglobin). This test can be used for diagnostics,
for screening, and for remission monitoring as well. We analyze clinical data, test various
machine learning methods and select the best approach to these problems. Three family
of methods, decision trees, kNN (including advanced and adaptive kNN) and probability
density evaluation with radial basis functions, are used for classification and risk esti-
mation. Several pre-processing approaches were implemented and compared. The best
of them are used to create the diagnostic system. For the differential diagnosis the best
solution gives the sensitivity and specificity of 83.5% and 77%, respectively (using three
input features, CRP, Haptoglobin and standard clinical symptom). For the screening
task, the decision tree method provides the best result, with sensitivity and specificity
of 81.4% and >99%, respectively (using the same input features). If the clinical symp-
toms (Lymphadenopathy) are considered as unknown then a decision tree with CRP and
Hapt only provides sensitivity 69% and specificity 83.5%. The lymphoma risk evalua-
tion problem is formulated and solved. The best models are selected as the system for
computational lymphoma diagnosis and evaluation the risk of lymphoma as well. These
methods are implemented into a special web-accessed software and are applied to problem
of monitoring dogs with lymphoma after treatment. It detects recurrence of lymphoma
up to two months prior to the appearance of clinical signs. The risk map visualisation
provides a friendly tool for explanatory data analysis.
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1. Introduction
1.1. Biomarkers for canine lymphoma
Approximately 20% of all canine tumours are lymphoma [78]. The typical age of a
dog with lymphoma is 6-9 years although dogs of any age can be affected. The biggest
problem with cancer treatment in dogs or humans is the earlier diagnostics. Routine
screening can improve cancer care by helping pick up tumours that might otherwise be
missed.
The minimally invasive tests are needed for screening and differential diagnosis as
precursors to histological analysis. It is also necessary to monitor the late effects of
treatment, to identify or explain trends and to watch the lymphoma return. The modern
development of veterinary biomarker technology aims to answer these challenges. In
the discovery of cancer biomarkers the veterinary medicine follows human oncology with
some delay. The controversies, potentials biases, and other concern related to the clinical
application of biomarker assays for cancer screening are discussed in [29]. There is
increasing interest in the study of prognostic and diagnostic biomarker proteins for canine
lymphoma [55].
Identification of several biomarkers for canine lymphoma has been reported during
the last decade:
• The proteomic evaluation of lymph nodes from dogs with B-cell lymphoma (11
cases) was compared to those from unaffected controls (13 cases). The expres-
sion of prolidase (proline dipeptidase), triosephosphate isomerase and glutathione
S-transferase was decreased in the samples from the lymphoma cases and the ex-
pression of macrophage capping protein was increased [49].
• The surface-enhanced laser desorption-ionization time-of-flight mass spectrometry
(SELDI-TOF-MS) was used to identify biomarker proteins for B-cell lymphoma in
canine serum. 29 dogs with B-cell lymphoma and 87 control dogs were involved in
the study. Several biomarker protein peaks in canine serum were identified, and
a classification tree was built on the basis of 3 biomarker protein peaks. It was
reported that with 10-fold cross-validation of the sample set, the best individual
serum biomarker peak had 75% sensitivity and 86% specificity and the classifica-
tion tree had 97% sensitivity and 91% specificity for the classification of B-cell
lymphoma [21].
• A commercially available canine lymphoma screening test was developed by PetScreen
Ltd [66]. Serum samples were collected from 87 dogs with malignant lymphoma and
92 control cases and subjected to ion exchange chromatography and SELDI-TOF-
MS analysis. Nineteen serum protein peaks differed significantly (p<0.05) between
the two groups based on normalized ion intensities. From these 19 peaks, two differ-
entiating biomarkers emerged with a positive predictive value (PPV) of 82%. These
biomarkers were used in a clinical study of 96 dogs suspected of having malignant
lymphoma. A specificity of 91% and sensitivity of 75% was determined, with a
PPV of 80% and negative predictive value (NPV) of 88%. Later on, these peaks
were identified as two acute phase proteins: Haptoglobin (Hapt) and C-Reactive
Protein (CRP) [2].
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• Some qualitative alterations were identified in dogs with lymphoma in the pro-
teomic study [5]; 21 dogs included in the study had high grade lymphoma confirmed
cytologically (16 cases) or histologically (five cases). The increased concentrations
of haptoglobin in the sera of dogs with lymphoma could account for increased
levels of α2 globulins, α2 macroglobulin, α-anti-chymotrypsin and inter-α-trypsin
inhibitor, which were identified concurrently.
• Vascular endothelial growth factor (VEGF), metalloproteinase (MMP) 2 and 9
transforming growth factor beta (TGF-β) were tested in 37 dogs with lymphoma,
13 of which were also monitored during chemotherapy. Ten healthy dogs served as
control. Lymphoma dogs showed higher activity of MMP-9 (p<0.01) and VEGF
(p<0.05), and lower TGF-β than controls, and a positive correlation between act-
MMP-9 and VEGF (p<0.001). During chemotherapy, activity MMP-9 and VEGF
decreased in B-cell lymphomas (p<0.01), suggesting a possible predictive role in
this group of dogs [3].
For use in clinics, the biomarkers should be identified and validated in preclinical
settings and then validated and standardized using real clinical samples [56]. Intensive
search of biomarkers requires standardisation of this technology [48]. Proteins discov-
ered in the research phase may not necessarily be the best diagnostic or therapeutic
biomarkers. Therefore, after identification of a biomarker (Phase 1), the clinical assays
are necessary to investigate if the biomarker can truly distinguish between disease versus
control subjects (Phase 2). Then special retrospective and prospective research is needed
for sensitivity and specificity analysis (Phases 3 and 4). Finally, the cancer control phase
is needed (Phase 5) to “evaluate role of biomarker for screening and detection of cancer
in large population” [48]. Discovery and identification of a promising biomarker does not
mean that it will successfully go through the whole standardised procedure of testing
and evaluation.
1.2. Acute phase proteins as lymphoma biomarkers
Acute phase proteins are now understood to be an integral part of the acute phase
response which is the cornerstone of innate immunity [17]. They have been shown to
be valuable biomarkers as increases can occur with inflammation, infection, neoplasia,
stress, and trauma. All animals have acute phase proteins, but the major proteins of this
type differs by species. Acute phase proteins have been well documented in laboratory,
companion, and large animals. After standardized assays, these biomarkers are available
for use in all fields of veterinary medicine as well as basic and clinical research [17].
Acute phase proteins including alpha 1-acid glycoprotein [60, 27, 74], C-Reactive
Protein (CRP) [52, 54, 66, 2], and Haptoglobin (Hapt) [54, 66, 2], have been evaluated
as tumor markers. Nevertheless, as is mentioned in review [29], it is still necessary to
prove that these biomarkers are clinically useful in cancer diagnosis. Some authors even
suggest that the non-specific serum biomarkers indicate inflammatory response rather
than cancer [35].
In our research we evaluate the role of two biomarkers, CRP and Hapt, for screening
and detection of lymphoma, for differential diagnosis of lymphoma and for monitoring of
lymphoma return after treatment. Our research is based on the PetScreen Canine Lym-
phoma Blood Test (cLBT). This is advanced technology to detect lymphoma biomarkers
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present in a patient’s serum [2]. The cLBT evaluates the concentration of two acute phase
proteins: Hapt and CRP. High levels of these biomarkers indicates a high likelihood that
the patient has lymphoma. The cLBT provides a minimally invasive alternative to a fine
needle aspirate as a precursor to histological diagnosis of the disease. The cLBT should
be used for differential diagnosis when a patient is suspected of having lymphoma by
showing classical symptoms such as generalized lymphadenopathy, PU/PD and lethargy
(we call all such cases the clinically suspected ones). It may be also useful in the moni-
toring of lymphoma return. In summary, the test provides:
• A simple blood test requiring only 2ml of blood taken as part of existing biochem-
istry/haematology work up. Results are available the same day.
• A minimally invasive procedure.
• An alternative to taking an FNA sample and the associated risks of failing to
retrieve sufficient lymphoid cells or encountering poor preservation of the cells.
• A monitoring tool to assess treatment progression and to detect recurrence.
Some of our previous results of canine lymphoma diagnosis are announced in [2, 53].
1.3. The structure of the paper
The description of the database and statement of the problems are represented in
Section 2. Two cohorts are isolated in the database and two problems are formulated:
(i) differential diagnostic in clinically suspected cases and (ii) screening. The isolation of
the clinically suspected cohort is necessary for formulation of the problem of differential
diagnostics and selection of the appropriate methods. The healthy cohort and formulation
of the screening problem demands the use of a prior probability of lymphoma and forbids
the use of class weights as a parameter to select the best solution. This means that the
weights of classes are determined by the prior probability. Both problems (differential
diagnostics and screening) are formulated as problems of probabilistic risk evaluation
[10]. Usual classifiers provide a decision rule and give the answer in the form “Yes” or
“No” (cancer or not cancer, for example). We almost never can be sure that this “Yes”
or “No” answer is correct. Therefore the evaluation of probability may be more useful
than just a binary answer. If we evaluate the posterior probability of lymphoma under
given values of features then we can take the decision about the next step of medical
investigation or treatment. Probabilistic risk evaluation supports decision making and
allows to evaluate the consequences of the decisions (risk management [10]).
Section 3 presents a brief review of the data mining methods employed in biomarker
cancer diagnosis. We introduce the methods used in our work for the analysis of canine
lymphoma. The detailed description of these methods is given in Appendix. Three used
methods are described:
• Decision trees with three different impure-based criteria: information gain, Gini
gain and DKM [67].
• K nearest neighbors method (KNN). Three versions of KNN methods are used:
KNN with Euclidean distance [16], KNN with Fisher’s distance transformation,
and the advanced adaptive KNN [28]. All the three methods use statistical kernels
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to weight an influence of each of the k nearest neighbors to evaluate the risk of
lymphoma. The KNN method with Fisher’s distance transformation is much less
known. We use the geometrical complexity [86] for comparison of different KNN
methods.
• Probability density function estimation (PDFE) [69]. We use PDFE for direct
evaluation of the lymphoma risk.
The decision trees and KNN classifiers are also used for evaluation of probability.
The way back from the probability estimate to classification rule is simple, just define
the threshold. The criterion of selection of the best classifier is the maximum sum of
sensitivity and specificity or the furthest from the “completely random guess” classifier.
We also compare performance of this selection criterion with some other criteria: the rel-
ative information gain (RIG) from the classifier output to the target attribute, accuracy,
precision, and F -score.
We use classical methods, and the main building blocks of the algorithms are well
known. Nevertheless, some particular combinations of methods may be new, for example,
combination of discriminant analysis with Advanced KNN (see Appendix). We have
tested automatically thousands of combinations, and the best combination for each task
has been selected.
Section 4 contains the description of the best solutions obtained for differential di-
agnostic and screening problems. All features are analyzed from the point of view of
their usability for the lymphoma diagnostic and risk evaluation. We present the case
study for both problems: for the diagnostics problem we have tested 25,600,000 variants
of the KNN method, 5,184,400 variants of decision tree algorithms and 3,480 variants of
the PDFE method; for the screening task we have tested 51,200 variants of KNN and
advanced KNN parameters, 10,368 variants of decision trees and 3,480 variants of PDFE.
The versions differ by impurity criteria, kernel functions, number of nearest neighbors,
weights and other parameters. The best results are implemented in web-accessed software
for the diagnosis of canine lymphoma (implemented in Java 6).
The obtained results provide the creation of a more reliable diagnostic, screening and
monitoring system for canine lymphoma. The first application of the developed system
shows that the risk of lymphoma (cLBT score) defined after lymphoma treatment allows
prediction of time before relapse of lymphoma. If after treatment of lymphoma the cLBT
is performed regularly, it detects recurrence up to two months prior to the appearance
of physical signs.
2. Database description and problem statement
2.1. Database
The original database contains 303 records (dogs) with four categorical input fea-
tures: Sex, Lymphadenopathy, Neutered and Breed and three real valued features: Age
and concentrations of two acute phase proteins: Haptoglobin (Hapt) and C-Reactive
Protein (CRP). A part of serum samples was collected by PetScreen from dogs undergo-
ing differential diagnosis for lymphoma and also collected at veterinary practices in the
USA [2, 66]. Another source is the Pet Blood Bank which stores the blood of healthy
dogs. Lymphoma positive serum samples were confirmed either by excisional biopsy
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or fine needle aspirate and non-lymphoma serum samples were confirmed to be free of
lymphoma at a minimum of 6 months after the sample was taken [2, 66].
Breed may be important for lymphoma diagnosis. For example, the boxer, bulldog
and bull mastiff breeds have a high incidence of lymphoma [62]. The relatively small
number of records in our database has limited our ability to detect breeds with an elevated
risk. We exclude this feature because there are 54 different breeds in 204 records (less
than four records of each breed) and 99 missed values. This amount of known data
for a categorical feature with 54 different values is not sufficient for diagnosis without
clustering of breeds (numerosity reduction is needed). The well-developed imputation
methods [70] also cannot be applied directly without numerosity reduction because of
insufficient information.
The target feature Lymphoma is binary: “Positive” for a dog with lymphoma and
“Negative” for a dog without lymphoma. Three attributes contain missed values: Sex
contains 96 (35%); Neutered contains 107 (38%); Age contains 101 (36%).
2.2. Two cohorts and two problems
Isolating of two cohorts. The database analysis shows that the samples are hetero-
geneous: two different cohorts of data can be distinguished in the database. There were
two different sources of data: dogs undergoing differential diagnosis for lymphoma and
the Pet Blood Bank (the blood of healthy dogs) [2].
The existence of two so different sources of data entails the presence of two different
cohorts of patients in the database. The first cohort is entitled “clinically suspected” and
contains records collected by PetScreen from dogs undergoing differential diagnosis. All
dogs in this cohort have been referred for differential diagnosis by veterinary practitioners.
The vets decide that these dogs are clinically suspected on the base of one or more clinical
symptoms. It is not possible to find a posteriori these symptoms for each instance and
we have to introduce a new synthetic attribute: “clinically suspected”. The cohort of
clinically suspected instances should be considered separately for differential diagnosis
purposes and we propose to treat each case referred to the differential diagnosis as a
clinically suspected one. The second cohort is entitled “healthy” and contains records
obtained from healthy dogs courtesy of the Pet Blood Bank.
The additional confirmation of existence of two cohorts is the differences in statistics
of the attributes for these cohorts. In accordance with expert estimations, the prior
probability of lymphoma is located between 2% and 5% in the canine population. The
number of records of patients with lymphoma is 97 or 32% of all the records in the
database. All these cases have been clinically suspected and form 42% of the clinically
suspected cases. This imbalance entails the usage of specific methods to solve screening
tasks. The “clinically suspected” feature was added to the database to identify the two
cohorts. The values of feature “clinically suspected” were defined by using additional
information from veterinary cards.
The existence of the two cohorts allows us to formulate two different problems: the
problem of differential diagnosis and the problem of screening.
Differential diagnosis. The problem of differential diagnostic can be formulated as a
problem of lymphoma diagnosis for patients with some clinical symptoms of lymphoma.
To solve this task we use the clinically suspected samples. A diagnostic problem is a
usual classification problem and all classification methods can be used. We use three
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types of classification methods: KNN, decision tree and the method based on probability
distribution function estimation. Each of these methods is described in Section 3. The
first two methods have an auxiliary parameter “weight” of the positive class wp.
Screening. The problem of screening can be formulated as a problem of evaluation
of lymphoma risk for any dog. The sample for this problem includes all the database
records. The experts’ estimation of prior probability of lymphoma is between 2% and
5% however the fraction of patients with lymphoma records in the database is 32%. To
compensate for this imbalance all methods take into account the prior probability of
lymphoma and the weights of classes are defined by prior probability.
3. Methods
3.1. Data mining methods for biomarker cancer diagnosis
Extraction diagnostic biomarkers for cancer, their validation and testing for clini-
cal use is considered now as a data analysis challenge [31]. The classical methods of
supervised classification are widely used to meet this challenge: linear and quadratic
discriminant analysis [6, 8, 45, 79], decision trees [1, 9, 30, 47, 59, 63, 72, 77, 85], lo-
gistic regression [4, 8, 38, 39], k nearest neighbors (KNN) approach [30, 63, 79, 80] and
na¨ıve Bayes model for probability density function estimation [8, 61]. Artificial neural
networks are used for the identification of cancer biomarkers and cancer prediction as a
flexible tool for supervised learning [7, 30, 41, 63, 76, 77, 40]. During the last decade,
applications of support vector machines [26, 43, 63, 79], and ensemble learning (random
forests, committees of decision trees, boosting methods) [15, 42, 43, 58, 82, 84] have been
intensively developed.
Most of the works combine and compare several methods, for example, discriminant
analysis, KNN and support vector machines [79], decision trees, KNN, and artificial
neural networks [30], discriminate analysis, random forest, and support vector machine
[58], decision trees, bagging, random forests, extra trees, boosting, KNN, and support
vector machines [23], linear discriminant analysis, quadratic discriminant analysis, KNN,
bagging, boosting classification trees, and random forest [82].
Supervised classification and regression methods are combined with dimensionality
reduction methods such as linear and non-linear principal component analysis [8, 24,
32, 37, 77] or moment-based approach [73]. Several hybrid systems are developed with
combinations of supervised classification and unsupervised clustering [8, 83].
The classical decision trees or KNN approach (or both) usually serve as bases for
comparison when evaluating supervising classification. It is necessary to stress that
there are many versions of algorithm even for a single decision tree or KNN. In this
paper, we systematically test many versions of these basic algorithms on the problem of
canine lymphoma differential diagnosis and screening.
We use three types of classification methods to evaluate the risk of lymphoma for the
problems of differential diagnosis and screening: decision tree, KNN and PDFE. Each
of these titles covers many different algorithm. Detailed description of these families of
algorithms used is presented in Appendix. We aim to select the best one for the given
problem. Simultaneously the best subset of input attributes should be selected.
Totally we have tested 10,368 trees for the screening problem. For the task of dif-
ferential diagnostic we vary the weight of class of patients with lymphoma from 0.1 to
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50. For the differential diagnostic problem 5,184,400 variants of decision trees have been
tested.
We have tested 51,200 sets of parameter values for the screening. For the differen-
tial diagnostic, we vary the weight of class of patients with lymphoma from 0.1 to 50;
25,600,000 variants of KNN method have been tested.
We have tested 3,840 variants of PDFE for each problem.
3.2. Data transformation, evaluation and weighting
The CRP and Hapt features are the concentrations of the two proteins. It is well-
known that in many chemical applications the logarithm of concentration (the chemical
potential) is more informative and useful then the concentration itself [81]. Therefore,
we test all the methods for concentrations of CRP and Hapt (in the “natural” units of
concentration) and for logarithms of the concentrations (in the logarithmic coordinates).
All real valued features are divided by their standard deviation. If CRP and Hapt are used
in logarithmic transformed form then initially we perform logarithmic transformation and
then divide by the standard deviation of the logarithmic transformed feature. For the
KNN and PDFE all the binary input features are coded by 0 and 1.
For feature evaluation and selection we calculate the Relative Information Gain (RIG)
[67] which is the natural tool to estimate the importance of input features for the cat-
egorical target feature. For this purpose, real data have been binned (organized into
groups).
We use two types of weights: prior weights of classes and weight of positive class.
Really, we use the weights of instances instead of weights of classes. For the differential
diagnosis and screening problems both types of weights are defined for different reasons:
for the screening problem we have the prior probability of lymphoma for the whole dog
population; for the differential diagnosis problem we have no prior probability but can
use the auxiliary weight of the positive class to search for the best classifier. We use the
following notations: p is the prior probability of lymphoma, NL is the number of patients
with lymphoma, NCS is the number of all clinically suspected patients and NH is the
number of healthy patient.
For the screening problem the weight of the class of patients with lymphoma is equal
to p. The weight of one patient with lymphoma is equal to wL = p/NL. In fact, this is
the weight of any record of the clinically suspected cohort. The total probability must
be equal to 1. This means that the sum of weights of all records must be equal to 1.
Therefore, the weight of each record of a healthy patient is wH = (1−wLNCS)/NH. For
the screening problem the auxiliary weight of the positive class cannot be used (is equal
to 1).
For the differential diagnosis problem there is no prior probability. The auxiliary
weight of positive class may be any positive number.
To work with imbalanced dataset we employ two data simulation methods for over-
sampling of the minority class.
The first approach (“Rectangular”) uses the random generation of N new instances
for each given sample from the minority class by formulas
xnew = x+ σxWrx (1)
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where σx is the standard deviations, rx is a random variable uniformly distributed in
interval (-1,1), W is the average Euclidean distance from the given sample to k near-
est neighbors of the same class. (The Euclidean distance is calculated in the plane of
dimensionless variables normalized to unite variance.)
The second approach is synthetic minority over-sampling technique (SMOT) [12].
It also uses the random generation of N new instances for each given sample from the
minority class. For a given k, we find k nearest neighbors of the given sample of the same
class. Each new instance is randomly situated on the straight line interval which links
the given sample with a randomly selected nearest neighbor (from k neighbors found).
3.3. Selection of the best algorithms
We have many algorithms (variants of algorithm parameters) and we need to select
the best algorithm. In this study we have considered two possible approaches: (i) use of
the test set and (ii) Leave One Out Cross Validation (LOOCV). The preference for using
test set is the speed: for each algorithm one model construction is sufficient. The model
construction means the forming of the decision tree, or identifying k nearest neighbors,
and computing the inverse covariance matrix for PDFE. LOOCV is more expensive: the
number of model constructions is equal to the number of instances. Nevertheless, for a
relatively small sample exclusion of a sufficiently large test set from learning may lead
to the strong scattering of the evaluation result. We split the database into training set
(80%) and test set (20%) 100 times independently and find large variance of the estimated
sensitivity and specificity. The values vary from 30% to 100%, and the best version of the
algorithm cannot be defined unambiguously. Therefore, we use LOOCV for evaluation of
sensitivity and specificity and for selection of the best algorithm. An extensive simulation
study of cross-validation for three classification rules, Fisher’s discriminant analysis, 3NN,
and decision trees (CART) using both synthetic and real breast cancer patient data was
performed in [11]. It was demonstrated that cross-validation is less biased than some
other methods but overestimates the number of errors for small samples.
The next question is what indicator has to be used as a measure of algorithm accuracy.
We can calculate the accuracy of classification as a ratio of correctly classified cases
among all cases. Also the sensitivity and specificity can be used as such a measure. The
classification accuracy is appropriate when numbers of examples of different classes are
balanced. In our database the fraction of lymphoma patients is equal to 32% for the
screening problem and 42% for the differential diagnosis problem. This means that the
algorithm selected by classification accuracy can be shifted to good specificity and poor
sensitivity. Other commonly used measures of classification quality is the area under
Receiver Operating Characteristic (ROC) [75]. The sum of specificity and sensitivity
is the distance from curve to the main diagonal which corresponds to the ‘completely
random guess’ classifier. We suggest considering the classifier with maximum sum of
specificity and sensitivity as the best.
4. Results
4.1. Feature evaluation by information gain
We need to find how much information about the diagnosis contain the inputs. For
this purpose, real data have been binned (organized into groups). The bins have ap-
proximately equal depth; the boundaries of bins are represented in Table 1. Table 2
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Table 1: Real attributes and bins.
Feature min max Upper bounds of bins
Age 0.67 17 3, 6, 8, 11, 20
CRP 0 124 0.6, 2.5, 11, 27, 125
Hapt 0 18 0.2, 1.7, 4, 7.5, 20
Table 2: Relative information gain about the “Lymphoma” feature.
RIG under given L
Tested feature RIG L=Y L=N
L 28.92% – –
CRP binned 24.38% 15.00% 23.52%
Hapt binned 07.02% 01.76% 14.32%
Age binned 06.07% 01.62% 09.39%
Sex 00.95% 03.79% 22.84%
Neutered 00.06% 00.50% 00.47%
contains values of RIG for the target feature Lymphoma from any input feature. RIG is
calculated for the whole database and for two samples: (Y) with L=“Y” and (N) with
L=“N” (we use the abbreviation L for Lymphadenopathy). The RIG from Neutered is
always less than 1% and this feature is excluded from the further study.
We calculate the RIG for Lymphoma from all the input features together. The
calculated value of RIG is 83%. This gives us an estimate of the expected classification
accuracy. Therefore, we do not expect to produce classifiers without misclassifications.
The number of input attributes is five and the problem of feature selection can be
solved by exhaustive search. Table 2 shows that the most informative attributes are
Hapt (H) and CRP (C). These features are included into all tested sets of input features.
The various combination of Age (A), Sex (S) and Lymphadenopathy (L) are included
into tested input sets. In total, eight input feature sets are formed. Each set is denoted
by abbreviation of included features: CH, CHA, CHL, CHS, CHAL, CHAS, CHLS and
CHALS.
The distributions of the real valued features are non-normal. It means that we can-
not use any methods based on assumption of normality. The distribution diagram for
Lymphoma is represented in Fig. 1. The diagram shows that only four records with-
out lymphadenopathy have a positive Lymphoma diagnosis. It means that the decision
“all dogs without lymphadenopathy have no lymphoma” generates only 4 false negative
errors and truly identifies 93 dogs without lymphoma.
4.2. The best algorithms
The criteria developed for choosing the best solution suggest selecting the following
algorithms. The ROC curves for the selected classifiers are depicted in Fig.2.
Differential diagnostic problem. The best algorithm is the decision tree with three
input features: a linear combination of the concentrations of CRP and Hapt, and Lym-
phadenopathy. The tree is formed with DKM as the splitting criterion. The sensitivity
of this method is 83.5%, specificity is 77%. The ROC integral for this method is 0.879
(Fig. 2a).
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Figure 1: Distribution of Lymphoma diagnosis.
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Figure 2: ROC curves for (a) the best algorithm for differential diagnosis (ROC integral 0.879), (b) the
best algorithm for differential diagnosis with CRP and Hapt only (ROC integral 0.780), (c) the best
algorithm for screening (ROC integral 0.917), and (d) the best algorithm for screening with CRP and
Hapt only (ROC integral 0.771).
In the case when Lymphadenopathy is considered as unknown we use a decision tree
which only uses CRP and Hapt. The tree is formed with Information gain as a splitting
criterion. The best version uses input features in linear combinations after logarithmic
transformation. The sensitivity of this method is 81.5%, the specificity is 76%. The ROC
integral (Fig. 2b) for this method is 0.780.
Screening. The best classifier for the screening problem is the decision tree with three
input features: the concentrations of CRP and Hapt, and Lymphadenopathy. The tree
is formed with DKM as a splitting criterion. The concentrations of CRP and Hapt are
used separately (not in linear combinations). The sensitivity of this method is 81.4%
and specificity is >99% (no false negative results in one-leave-out cross-validation). The
ROC integral is 0.917 (Fig. 2c). In the case when Lymphadenopathy is considered as
unknown we use a decision tree with CRP and Hapt only. The tree is formed with Gini
gain as the splitting criteria. The concentrations of CRP and Hapt are used separately.
The sensitivity is 69%, the specificity is 83.5%. The ROC integral is 0.771 (Fig. 2d).
The classifiers for screening are prepared using the mixture of clinically suspected
patients (Lymphadenopathy=Y) with the patients without lymphadenopathy. Applica-
tion of these classifiers for screening of dogs without clinical symptoms (Lymphadenopa-
thy=N) requires additional tests because there are only four cases of dogs with lymphoma
with Lymphadenopathy=N in the database (see Fig. 1). For the preliminary analysis of
11
Table 3: Sensitivity and specificity for extended dataset.
Method Sensitivity Specificity
Rectangular 89.1 62.2
SMOTE 88.3 65.2
Table 4: Sensitivity and specificity (%) for the best models selected by different criteria
Sens+Spec RIG Accuracy Precision F -score
Method Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec
DT 83.5 77.0 83.5 77.0 79.4 79.3 78.4 80.0 83.5 77.0
KNN 79.4 75.6 84.5 70.4 79.4 75.6 4.1 100.0 84.5 70.4
PDFE 83.5 68.9 83.5 68.9 77.3 74.8 70.1 78.5 83.5 68.9
this problem we apply both data simulation methods for over-sampling of the minority
class, Rectangular (1) and SMOT.
We select N = 10 and k = 3 in each method and add synthetic data to the instances
from the original database with Lymphadenopathy=N and positive lymphoma diagnosis.
The new database has well balanced classes. For both methods, the two best decision
trees (one for Lymphadenopathy=Y and one for Lymphadenopathy=N) together demon-
strate in LOOCV the results presented in Table 3. We see that with the simulated data
specificity decreases. Therefore, it is desirable to collect more instances with lymphoma
but without observable lymphadenopathy (Lymphadenopathy=N) for the validation of
screening algorithms.
Other criteria. The value of the Hosmer-Lemeshow [34] statistics for the differential
diagnosis algorithm with three input value (CHL) is 12.73. It shows that with p-value
greater than 10% the distribution of estimated probabilities coincides with the distri-
bution of diagnosis. This test does not consider the prior probability and cannot be
applied for the screening problem. Efron’s pseudo R2 [19] shows that classifiers which
use Lymphadenopathy explain about 40% of total variance. McFaden’s pseudo R2 [50]
for the differential diagnosis problem classifier, which uses Lymphadenopathy, has 38%
greater log likelihood than the null model ones. For the screening problem the classifier
which uses Lymphadenopathy has 45% greater log likelihood than the log likelihood of
null model which is based on prior probability.
We employ the Sensitivity + Specificity criterion for the best model selection. There
exist many other criteria, for example, relative information gain (RIG) from the classifier
output to the target attribute (Lymphoma, in our case), Accuracy ([“True positive” +
“True negative”]/”Number of instances”), Precision (“True positive”/“Number of pos-
itive labels”), where “Number of positive labels” is the number of samples labeled as
positive, i.e. “True positive” + “False positive”, F -score that is the harmonic mean of
Precision and Sensitivity (F= 2×Precision×Sensitivity/[Precision + Sensitivity]). We
compare performance of these criteria on the test task of selection of the best model for
the data set CHL without logarithmic transformation of concentrations. Table 4 repre-
sents the sensitivity (Sens) and specificity (Spec) for the best models which are selected
by each criterion.
As we can see from this test, only the criterion Precision sometimes gives significantly
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Figure 3: The maps of lymphoma risk for male and female dogs: (a) PDFE map for male, (b) decision
tree map for male, (c) KNN map for male, (e) PDFE map for female, (f) decision tree map for female,
(g) KNN map for female, and (d) is the legend. Disclaimer: these colored maps are for qualitative
illustration and understanding and not for diagnosis of individual patients where the more detailed
maps and exact numerical values are needed.
different results (very precisely all the positive labels are true positive but many false
negative results occur). All other criteria produce similar results.
Risk evaluation and risk mapping. All classifiers used in our study can calculate the
risk of lymphoma at an arbitrary point. We can use this capability to form a map of
risk. To visualize data with more than two dimensions several types of screens can be
used: coordinate planes, PCA, non-linear principal graphs and manifolds [24, 25]. For
this study we use the plane of CRP and Hapt concentrations. The explanation of colours
is depicted in the legend included at the right of each figure.
We use risk maps to generate hypotheses about the impact of input features. For
example, let us consider the risk of lymphoma in relation to sex for clinically suspected
cohort. There are 24 records with lymphoma and 54 records without lymphoma among
female records and 38 and 43 records with and without lymphoma correspondingly among
male records in the database of clinically suspected cases. The frequencies of lymphoma
for female and male are here 31% and 47% correspondingly. This probability difference
can be uniformly distributed in the space of the input attributes but can be condensed in
some area on the map. To check this hypothesis we form the risk map for the three best
classifiers one of each type for three input attributes: CHS (CRP, Hapt and sex). The
best PDFE parameters are concentrations of CRP and Hapt, 9 nearest neighbors and
Gaussian kernel (Fig. 3a, e). The best decision tree parameters are linear combinations of
CRP and Hapt after logarithmic transformation, Information gain as a splitting criterion
and the weight of class with lymphoma equals 1.8 (Fig. 3b, f). The best KNN options
are logarithmic transformed CRP and Hapt, Euclidean distance, 15 nearest neighbors
and Gaussian kernel for voting (Fig. 3c, g).
Fig. 3 shows that for each classifier there are two regions: the big sex independent area
in right side and small sex dependent area in left side. In this area, the risk of lymphoma
may depend on the steroid hormones. This hypothesis needs additional verification.
Applying the selected methods to lymphoma treatment monitoring. Prognosis and
prediction tools give the possibility to more individualised treatments of cancer patients
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Figure 4: Monitoring results: the number of weeks before relapse of lymphoma in dependence of cLBT
score.
[8]. We have applied the tools we developed to the problem of monitoring of dogs after
treatment for lymphoma. The canine lymphoma blood test was subjected to a blind
retrospective study on serum collected from 57 dogs over four years. The cLBT ranks
the remission status from 0 to 5 according to PDFE lymphoma risk evaluation, where 0
indicates complete remission, 5 equates to active diseases and a score of 3 represents a
border line result. The study demonstrated that dogs regularly giving a cLBT score of 2
or lower remained in remission, whereas an increase in the score to 3 or more indicated
that the disease was recurring.
The first important result is that the score of the test immediately after treatment is
very informative for predicting the time before relapse. Fig. 4a shows that for dogs with
cLBT score between 3 and 4 the time of lymphoma relapsing is about four weeks; for
dogs with cLBT score 2 the time of lymphoma relapsing is greater than four weeks and
less than eight weeks, and for dogs with cLBT score 1 the time of lymphoma relapsing
is greater than eight weeks.
The second important result is that the cLBT score indicates the relapse of lymphoma
before the clinical symptoms reappear. The study found that the test detected recurrence
up to two months prior to the appearance of physical signs. These results strongly support
the monthly basis monitoring of lymphoma patients in remission. The properly predicted
time before relapse gives the possibility for better treatment planning and we expect that
it may increase survival rate.
5. Conclusion
We formulate and analyze the problem of differential diagnosis of clinically suspected
cases and the problem of screening. The criteria to select the best classifier for each prob-
lem are chosen. These criteria allow the selection of the best algorithms. For differential
diagnosis the best solution is the decision tree with three input features: concentrations
of CRP and Hapt, and Lymphadenopathy. The tree is formed with DKM as a split-
ting criterion. In this tree at each node the linear combination of CRP and Hapt are
used (Fisher’s approach). Synthesis of decision trees and linear discriminant analysis is
proven to be optimal in some cases. The sensitivity of the best decision tree is 83.5%,
the specificity is 77%.
The best result is obtained for screening by the decision tree which uses three input
features: the concentrations of CRP and Hapt, and Lymphadenopathy. CRP and Hapt
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are used separately. DKM is used as the splitting criterion. The sensitivity of this
method is 81.4%, the specificity is >99% (no false negative results in one-leave-out cross-
validation).
For screening on the base of two biomarker concentrations only, without any clinical
symptoms, the best decision tree uses the concentrations of CRP and Hapt separately
and Gini gain as splitting criteria. The sensitivity of this tree is 69%, the specificity is
83.5%.
We compare our results with some current human cancer screening tests. The ac-
curacy of tests which based on single biomarkers is often worse. For example, the male
PSA test gives sensitivity approximately 85% and specificity 35% and the CA-125 screen
for human ovarian cancer provides sensitivity approximately 53% and specificity 98%.
Supplementation of CA-125 by several other biomarkers increases sensitivity of at least
75% for early stage disease and specificity of 99.7% [68]. For the PSA marker, using
age-specific reference ranges improved the test specificity and sensitivity, but did not
improve the overall accuracy of PSA testing [33].
The risk map visualisation is a friendly tool for explanatory data analysis. It provides
the opportunity to generate hypotheses about the impact of input features on the final
diagnosis. The risk of lymphoma (cLBT score) defined after lymphoma treatment allows
prediction of time before relapse of lymphoma. If after treatment of lymphoma the cLBT
is performed regularly, it detected recurrence up to two months prior to the appearance
of physical signs.
Canine lymphoma can be considered as a model for human non-Hodgkin lymphoma
[51]. The new diagnostic approaches can be applied for this disease.
There are several questions and directions the future work with the biomarkers CRP
and Hapt for canine lymphoma
• Further clinical testing of the screening classifier with special attention to the in-
stances with lymphoma but without obvious lymphadenopathy;
• Further clinical testing of the proposed lymphoma treatment monitoring system
to validate the hypothesis that properly predicted time before relapse improves
treatment planning and increases survival rate;
• Clustering of breeds for numerosity reduction and inclusion of this important fea-
ture in the diagnostic system;
• Selection of the optimal set of input features for lymphoma diagnosis from combi-
nations of CRP and Hapt with the results of routine blood tests.
6. Appendix: Three main groups of algorithms
6.1. Decision tree
Decision tree is a method that constructs a tree like structure which can be used to
choose between several courses of action. Binary decision trees are used in this study.
The decision tree is comprised of nodes and leaves. Every node can have a child node.
If a node has no child node it is called a leaf or a terminal node. Any decision tree
contains one root node which has no parent node. Each non terminal node calculates its
own Boolean expression (i.e. true or false). According to the result of this calculation
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the decision for a given sample would be delegated to the left child node (“true”) or to
the right child node (“false”). Each leaf (terminal node) has a label which shows how
many samples of the training set belong to each class: nL is the number of cases with
lymphoma, nSCWL is the number of clinically suspected cases without lymphoma, nH is
the number of healthy cases. The probability of lymphoma is evaluated as a result of
the division of the sum of weights of positive samples in this leaf by the sum of weights
of all samples in the same leaf:
pL = nLWL/(nLWL + nSCWLWSCWL + nHWH).
For the screening problem WL = wL,WSCWL = wL and WH = wH. For the problem of
differential diagnosis WL = wp,WSCWL = 1 and WH = 0.
There are many methods to be used to develop a decision tree [67, 65, 36, 13, 22, 18].
We use the methods based on information gain, Gini gain, and DKM gain. Since the
screening problem defines the prior weights of classes, these weights must be considered.
There are two ways to implement prior weights. The simplest way is to multiply the
number of positive class cases in a leaf by the weight of the positive class, and the
number of negative class cases by the weight of the negative class and then calculate the
probability. In this study we use a different method: we modify the split criteria. Let us
consider one node and one binary input attribute with values 0 and 1. To form a tree
we select the base function for information criterion among
Entropy(nL, nn) = −
nL
nL + nn
log2
nL
nL + nn
−
nn
nL + nn
log2
nn
nL + nn
,
Gini(nL, nn) = 1−
n2L + n
2
n
(nL + nn)2
, DKM(nL, nn) = 2
√
nLnn
(nL + nn)2
,
where nL is the number of positive cases and nn is the number of negative cases. The
value of the criterion is the gain of the base function:
BG = Base(nL, nn)−
p0 + n0
nL + nn
Base(p0, n0)−
p1 + n1
nL + nn
Base(p1, n1),
where pa is the number of positive cases with value of input attribute a, na is the number
of negative cases with value of input attribute a, Base(m,n) is one of the base function
listed above. If each case has the weight the criterion is defined as
BGW = Base(w, v)−
w0 + v0
w + v
Base(w0, v0)−
w1 + v1
w + v
Base(w1, v1),
where w is the sum of weights of positive cases, v is the sum of weights of negative cases,
wa is the sum of weights of positive cases with value of input attribute equals a, va is the
sum of weights of negative cases with value of input attribute equals a. In this study we
use IGW instead of information gain, GGW instead of Gini gain and DKMW instead
of DKM gain.
For the screening problem wa = wLpa and va = wLnCSWL,a+wHnH,a, where nCSWL,a
is the number of clinically suspected cases without lymphoma with value of input at-
tribute a, and nH,a is the number of healthy cases with value of input attribute a. For
the problem of differential diagnosis wa = pa, va = na.
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There are several approaches for using real valued feature for forming decision tree.
The most commonly used approach suggests the binning of the real valued attribute
before form the tree. In this study we implement the method of on the fly binning: in
each node for each real valued attribute the best threshold is searched and then this
threshold is used to bin these feature in this node. The best threshold depends on the
split criteria used (information gain, Gini gain or DKM gain). We also use Fisher’s
discriminant to define the best linear combinations of real valued features [20] in each
node. This means that we use either each real valued attribute separately or one synthetic
real valued feature instead of all real valued input attributes. Pruning techniques are
applied to improve the tree. The specified minimal number of instances in the tree’s leaf
is used as a criterion to stop node splitting. This means that each leaf of the tree cannot
contain fewer instances than a specified number. For the case study we test the decision
trees which differ by:
• One of the three modified split criteria (information gain, Gini gain or DKM gain);
• The use of real-valued features in the splitting criteria separately or in linear com-
bination;
• The use of concentrations of Hapt and CRP or of logarithm of concentrations;
• The set of input features: CH, CHA, CHL, CHS, CHAL, CHAS, CHLS and
CHALS;
• The minimal number of instances in each leaf is varied between 3 and 30.
6.2. K nearest neighbors
The basic concept of KNN is: the class of an object is the class of a majority of its
k nearest neighbors [16]. This algorithm is very sensitive to distance calculation. There
are several commonly used variants of distance for KNN: Euclidean distance; Minkovsky
distance; distance calculated after some transformation of input space.
In this study we use three distances: the Euclidian distance, the Fisher’s transformed
distance and adaptive distance [28]. Moreover we use a weighted vote procedure with
weighting of neighbors by one of the standard kernel functions [44]. The KNN algorithm
is well known [16]. The adaptive distance transformations algorithm is described in
[28]. KNN with Fisher’s transformed distance is less well-known. For these methods
the following options are defined: k is the number of nearest neighbors, K is the kernel
function, kf is the number of neighbors which are used for distance transformation. To
define the risk of lymphoma we have to do the following steps:
1. Find the kf nearest neighbors of test point.
2. Calculate the covariance matrix of kf neighbors and Fisher’s discriminant direction.
3. Find the k nearest neighbors of the test point using the distance along Fisher’s
discriminant direction among the earlier found kf neighbors.
4. Define the maximum of distances from the test point to k neighbors.
5. For each class we calculate the membership of this class as a sum of points’ weights.
The weight of a point is the product of value of the kernel function K of distance
from this point to the test point divided by maximum distance and predefined point
weight.
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6. Lymphoma risk is defined as a ratio of the positive class membership to the sum
of memberships of all classes.
For the differential diagnosis problem the predefined weight of the lymphoma cases is
equal to wp and the predefined weight of the cases without lymphoma is equal to 1. For
the screening problem the predefined weight of clinically suspected cases is equal to wL
and for healthy cases the predefined weight is equal to wH. The adaptive distance version
implements the same algorithm but uses the other transformation on Step 2 and other
distance on Step 3. The Euclidean distance version simply defines kf = k and omits
Steps 2 and 3 of the algorithm. We test the KNN versions which differ by:
• The number of nearest neighbors is varied between 1 and 20;
• The use of concentrations of Hapt and CRP or of logarithm of concentrations;
• The set of input features: CH, CHA, CHL, CHS, CHAL, CHAS, CHLS and
CHALS;
• One of the three distances: Euclidean distance, adaptive distance and Fisher’s
distance.
• The kernel function for adaptive distance transformation;
• The kernel function for voting.
6.3. Probability density function estimation
We implement the radial-basis functions method [13] for probability density function
estimation [69]. For the robustness we also implement the local Mahalanobis distance
transformation [46]. There are three probabilities for the screening problem: Proba-
bility of lymphoma; Probability of belonging to the clinically suspected cohort without
lymphoma; Probability of being healthy. Each probability density function is estimated
separately by using nonparametric techniques. The total probability of lymphoma has
to be equal to the prior probability of lymphoma psL = p. The total probability of be-
longing to the clinically suspected cohort without lymphoma is defined by evaluation of
the probability of lymphoma in the clinically suspected cohort from data, and from the
given total probability of lymphoma in population:
psCSWL = p
s
L(NCS −NL)/NL.
The total probability of being healthy is equal to 1 minus the probability of belonging
to the clinically suspected cohort:
psH = 1− p
s
L − p
s
CSWL.
For the differential diagnosis we need to estimate two probabilities: probability of lym-
phoma and probability that there is no lymphoma. The prior probabilities of these classes
are defined by number of instances in each class:
pdL = NL/NCS and p
d
H = (NCS −NL)/NCS.
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Table 5: LOOCV time for one model
Classifier Time (sec)
Decision tree 0.22
KNN 0.00005
PDFE 0.14
For each point, k nearest neighbors from the database are defined. These k points are
used to estimate the covariance matrix and calculate the Mahalanobis distance matrix.
Then the radius of the neighborhood is estimated as a maximum of the Mahalanobis
distances from data point to each of k neighbors. The centre of one of the kernel functions
is placed at the data point [44]. The integral of any kernel function over the whole space is
equal to 1. There are NL cases of lymphoma and NL kernel functions are placed at these
points. The total probability is the integral of the sum of kernel functions and is equal
to NL but the total probability of lymphoma has to be equal to the prior probability p
t
L
(where t is ‘s’ for the screening problem and ‘d’ for differential diagnosis problem). It
means that the sum of kernel functions has to be multiplied by WL = p
t
L/NL.
The probability of lymphoma at an arbitrary point is estimated as products of weight
WL and the sum of values of kernel functions which are placed at data points that
correspond to records with lymphoma. Other probabilities are estimated analogously.
We use the following steps to evaluate the risk of lymphoma: (i) three (screening
problem) or two (differential diagnosis problem) probabilities are estimated and (ii) the
risk of lymphoma is defined as a ratio of the probability of lymphoma to the sum of all
probabilities. We test the PDFE versions which differ by:
• The number of nearest neighbors (it is varied between 5 and 30);
• The use of concentrations of CRP and Hapt or logarithm of the concentrations;
• The set of input features: CH, CHA, CHL, CHS, CHAL, CHAS, CHLS or CHALS;
• The kernel function which is placed at each data points.
6.4. Computational cost
Let us compare the computational cost of the most expensive procedure, LOOCV,
for these three types of algorithms. All software has been implemented in Java 6 with
one core usage. A computer with processor Intel(R) Core(TM) i7-3667U CPU 2.0GHz
2.5GHz with 8GB RAM under 64-bit Windows 7 Enerprise operation system has been
used. The test results are presented in Table 5. This is the time for LOOCV of one
model. For selection of the best decision tree this LOOCV routine was called 10,368
times for the screening problem and 5,184,400 times for the differential diagnosis, for the
best KNN method it was called 25,600,000 times and 3,840 times for the best PDFE.
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Summary
Lymphoma is one of the most frequent canine cancers. It can be also considered as a
model for human non-Hodgkin lymphoma. We develop technology for differential diag-
nosis of canine lymphoma, for screening and for remission monitoring. This technology
is based on a specific blood test.
The canine lymphoma blood test detects the levels of two biomarkers, the acute phase
proteins, C-Reactive Protein and Haptoglobin. This test can be used for diagnostics, for
screening, and for remission monitoring. We analyze clinical data, test various machine
learning methods and select the best approach to these problems.
Three family of methods, decision trees, kNN (including advanced and adaptive kNN)
and probability density evaluation with radial basis functions, are used for classification
and risk estimation. Several pre-processing approaches were implemented and compared.
The best of them are used to create the diagnostic system. For the differential diagnosis
the best solution gives the LOOCV sensitivity and specificity of 83.5% and 77%, respec-
tively (using three input features, CRP, Haptoglobin and the standard clinical symptom).
For the screening task, the decision tree method provides the best result, with sensitivity
and specificity of 81.4% and >99%, respectively (using the same input features), and if
the clinical symptoms (Lymphadenopathy) are considered as unknown then a decision
tree with CRP and Hapt provides sensitivity 69% and specificity 83.5%.
The lymphoma risk evaluation problem is formulated and solved. We use three meth-
ods to evaluate risk. The best models are selected as the system for computational
lymphoma diagnosis and evaluation the risk of lymphoma as well. These methods are
implemented into a special web-accessed software and are applied to problem of moni-
toring dogs with lymphoma after treatment. It detects recurrence of lymphoma up to
two months prior to the appearance of clinical signs and may help to optimize relapse
treatment. The risk map visualisation provides a friendly tool for explanatory data
analysis.
We compare our results with some current human cancer screening tests. The ac-
curacy of tests which based on single biomarkers is often worse. For example, the male
PSA test gives sensitivity approximately 85% and specificity 35% and the CA-125 screen
for human ovarian cancer provides sensitivity approximately 53% and specificity 98%.
Supplementation of the tests by several other biomarkers increases sensitivity and speci-
ficity.
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